Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pirfenidone is an oral antifibrotic medication primarily used for the treatment of idiopathic pulmonary fibrosis (IPF).Drug Interactions of PirfenidoneCYP1A2 InhibitorsConcomitant ···【more】
Article source：Captain MedicineRelease date：2026-02-04Recommended：52
The safety of pirfenidone has been evaluated in more than 1,400 subjects, of whom over 170 received pirfenidone treatment for more than 5 years in clinical trials.Precautions for U···【more】
Article source：Captain MedicineRelease date：2026-02-04Recommended：53
Nintedanib is a multi-targeted tyrosine kinase inhibitor; it can reduce the activity of fibroblasts in patients with idiopathic pulmonary fibrosis (IPF).What should be noted during···【more】
Article source：Captain MedicineRelease date：2026-02-03Recommended：52
In 2019, nintedanib became the first therapy approved by the FDA to slow the rate of lung function decline in adults with SSc-ILD.What side effects may occur with nintedanib?The fo···【more】
Article source：Captain MedicineRelease date：2026-02-03Recommended：55
Nintedanib is a small-molecule tyrosine kinase inhibitor that binds to growth factor receptors and inhibits the proliferation of fibroblasts.How to Take NintedanibTake this medicat···【more】
Article source：Captain MedicineRelease date：2026-02-03Recommended：53
Nintedanib is indicated for the treatment of diseases that cause scarring and hardening of the lungs, leading to breathing difficulties. It acts by inhibiting pathological changes ···【more】
Article source：Captain MedicineRelease date：2026-02-03Recommended：59
Elacestrant is the world’s first approved oral selective estrogen receptor degrader (SERD), indicated for the treatment of adult patients with estrogen receptor-positive (ER+), hum···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：59
Before starting elacestrant, discuss any questions or concerns with your medical team.What is the recommended dose of Elacestrant?Take one 345 mg tablet once daily. Patients should···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：63
Take elacestrant daily and always follow the guidance of your medical team strictly.How Effective is Elacestrant for Treatment?Elacestrant can significantly prolong the progression···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：58
Elacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive malignant tumors.Precautions for Elacestrant UseDyslipidemiaAmo···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：65
Anagrelide is indicated to reduce the risk of blood clots in patients with thrombocythemia (an abnormally high platelet count in the blood). Its mechanism of action is to inhibit p···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：43
Special caution is required when using anagrelide, as certain drugs may interact with it.What are the drug interactions of Anagrelide?Do not take this medicine with cisapride, dron···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：40
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
